Search Result

Results for "

4.96

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Apoptosis (2) BMX Kinase (1) Btk (1) Cholinesterase (ChE) (1) COX (1) Deubiquitinase (1) DGK (1) DNA/RNA Synthesis (1) EGFR (1) Endogenous Metabolite (1) Fluorescent Dye (3) GABA Receptor (1) iGluR (1) Leukotriene Receptor (1) MAP4K (1) MicroRNA (20) Microtubule/Tubulin (1) PD-1/PD-L1 (1) Prostaglandin Receptor (1) PROTACs (1)
By Research Areas:	Cancer (29) Endocrinology (1) Inflammation/Immunology (3) Neurological Disease (4)
Oligonucleotides:	miRNA mimics (5) miRNA agomirs (5) miRNA antagomirs (5) MicroRNAs (20) miRNA inhibitors (5)

Inhibitors & Agonists

Fluorescent Dye

Natural
Products

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-149666

BMS-496	DGK	Cancer
BMS-496 is adualDGKα/ζlipid kinase inhibitor, with theIC₅₀of 0.09 (DGKα) and 0.006 μM (DGKζ) .

HY-U00253

KP496	Leukotriene Receptor Prostaglandin Receptor	Inflammation/Immunology Endocrinology
KP496 is a selective, dual antagonist for Leukotriene D4 receptor and Thromboxane A2 receptor.

HY-R01474

*hsa-miR-496* mimic**	MicroRNA	Cancer
hsa-miR-496 mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

hsa-miR-496 mimic hsa-miR-496 mimic

HY-R03227

*mmu-miR-496b mimic*	MicroRNA	Cancer
mmu-miR-496b mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

mmu-miR-496b mimic mmu-miR-496b mimic

HY-RI01474

*hsa-miR-496* inhibitor**	MicroRNA	Cancer
hsa-miR-496 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

hsa-miR-496 inhibitor hsa-miR-496 inhibitor

HY-R03226

*mmu-miR-496a-5p mimic*	MicroRNA	Cancer
mmu-miR-496a-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

mmu-miR-496a-5p mimic mmu-miR-496a-5p mimic

HY-RI03227

*mmu-miR-496b inhibitor*	MicroRNA	Cancer
mmu-miR-496b inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

mmu-miR-496b inhibitor mmu-miR-496b inhibitor

HY-R01474A

*hsa-miR-496* agomir**	MicroRNA	Cancer
hsa-miR-496 agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-496 agomir hsa-miR-496 agomir

HY-R03227A

*mmu-miR-496b agomir*	MicroRNA	Cancer
mmu-miR-496b agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

mmu-miR-496b agomir mmu-miR-496b agomir

HY-RI03226

*mmu-miR-496a-5p inhibitor*	MicroRNA	Cancer
mmu-miR-496a-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

mmu-miR-496a-5p inhibitor mmu-miR-496a-5p inhibitor

HY-RI01474A

*hsa-miR-496* antagomir**	MicroRNA	Cancer
hsa-miR-496 antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-496 antagomir hsa-miR-496 antagomir

HY-RI03227A

*mmu-miR-496b antagomir*	MicroRNA	Cancer
mmu-miR-496b antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

mmu-miR-496b antagomir mmu-miR-496b antagomir

HY-R03226A

*mmu-miR-496a-5p agomir*	MicroRNA	Cancer
mmu-miR-496a-5p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

mmu-miR-496a-5p agomir mmu-miR-496a-5p agomir

HY-R04496

*rno-miR-496-5p mimic*	MicroRNA	Cancer
rno-miR-496-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

rno-miR-496-5p mimic rno-miR-496-5p mimic

HY-R04495

*rno-miR-496-3p mimic*	MicroRNA	Cancer
rno-miR-496-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

rno-miR-496-3p mimic rno-miR-496-3p mimic

HY-RI03226A

*mmu-miR-496a-5p antagomir*	MicroRNA	Cancer
mmu-miR-496a-5p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

mmu-miR-496a-5p antagomir mmu-miR-496a-5p antagomir

HY-RI04496

*rno-miR-496-5p inhibitor*	MicroRNA	Cancer
rno-miR-496-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

rno-miR-496-5p inhibitor rno-miR-496-5p inhibitor

HY-RI04495

*rno-miR-496-3p inhibitor*	MicroRNA	Cancer
rno-miR-496-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

rno-miR-496-3p inhibitor rno-miR-496-3p inhibitor

HY-R04495A

*rno-miR-496-3p agomir*	MicroRNA	Cancer
rno-miR-496-3p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

rno-miR-496-3p agomir rno-miR-496-3p agomir

HY-R04496A

*rno-miR-496-5p agomir*	MicroRNA	Cancer
rno-miR-496-5p agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

rno-miR-496-5p agomir rno-miR-496-5p agomir

HY-RI04495A

*rno-miR-496-3p antagomir*	MicroRNA	Cancer
rno-miR-496-3p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

rno-miR-496-3p antagomir rno-miR-496-3p antagomir

HY-RI04496A

*rno-miR-496-5p antagomir*	MicroRNA	Cancer
rno-miR-496-5p antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

rno-miR-496-5p antagomir rno-miR-496-5p antagomir

HY-19432

UBP-282	iGluR	Neurological Disease
UBP-282 is a potent, selective and competitive AMPA and kainate receptor antagonist. UBP-282 inhibits the fast component of the dorsal root-evoked ventral root potential (fDR-VRP) with an IC₅₀ value of 10.3 μM. UBP-282 antagonizes kainate-induced depolarisations of dorsal roots with a pA₂ value of 4.96 .

HY-16729A

Relenopride hydrochloride YKP10811 hydrochloride	5-HT Receptor	Inflammation/Immunology
Relenopride (YKP10811) hydrochloride is a specific and selective 5-HT₄ receptor agonist (K_i=4.96 nM). Relenopride hydrochloride has 120-fold and 6-fold lower affinity, respectively, for 5-HT_2A (K_i=600 nM) and 5-HT_2B receptors (K_i=31 nM) than for 5-HT₄. Relenopride hydrochloride increases gastrointestinal (GI) motility .

HY-146294

COX-2/5-LOX-IN-1	COX	Inflammation/Immunology
COX-2/5-LOX-IN-1 (compound 3a) is a potent and dual inhibitor of COX-2/5-LOX. COX-2/5-LOX-IN-1 is a benzothiophen-2-yl pyrazole carboxylic acid derivative. COX-2/5-LOX-IN-1 shows the most potent analgesic and anti-inflammatory activities surpassing that of Celecoxib and Indomethacin. COX-2/5-LOX-IN-1 shows potent COX-1, COX-2 and 5-LOX inhibitory activity with IC₅₀s of 12.13, 0.4 and 4.96 μM, respectively .

HY-D2874

6-AF488 tyramide	Fluorescent Dye	Others
6-AF488 tyramide is a bright, green fluorescent dye (Ex=496 nm, Em=524 nm). 6-AF488 tyramide is utilized as reporter fluorescent substrate of horseradish peroxidase (HRP)-catalyzed deposition for tyramide signal amplification (TSA). 5-FITC tyramide can be used for multiplex immunohistochemistry (mIHC) .

HY-162161

Flutax-2	Fluorescent Dye	Cancer
Flutax-2 is an active fluorescent derivative of Paclitaxel, binds to αβ-tubulin dimer polymerized. Flutax-2 can be used for imaging microtubules in live cells, isolated cytoskeletons and parasite (Ex/Em=496/526 nm) .

HY-158039

YCH2823	Deubiquitinase Apoptosis	Cancer
YCH2823 is an inhibitor of USP7 (IC₅₀ = 49.6 nM; K_d = 0.117 μM). YCH2823 shows significant efficacy in inhibiting TP53 wild-type and mutant tumors, with approximately 5-fold higher potency than FT671. YCH2823 induce apoptosis. YCH2823 synergistic effects with mTOR inhibitors .

HY-131010

Flutax-2 (5/6-mixture)	Fluorescent Dye Microtubule/Tubulin	Cancer
Flutax-2 (5/6-mixture) is an active fluorescent derivative of paclitaxel. Flutax-2 (5/6-mixture) binds to a polymerized α,β tubulin dimer. Excitation/emission wavelength: 496/524 nm. Paclitaxel, a diterpenoid secondary metabolite produced by Taxus species, can be used for the research of a variety of cancers .

HY-122140

ACG548B	Cholinesterase (ChE)	Neurological Disease
ACG548B (compound 24) is a potent inhibitor of acetyl- and butyrylcholinesterase (AChE and BChE) with IC₅₀s of 1.78 and 0.496 μM, respectively. ACG548B has higher AChE affinity and selectivity over BChE and ChoK (choline kinase). ACG548B can be uesd for the study of myasthenia gravis and neuromuscular blockade .

HY-80002

BMX-IN-1 5 Publications Verification BMX kinase inhibitor	Btk BMX Kinase	Cancer
BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys ⁴⁹⁶ in the BMX ATP binding domain with an IC₅₀ of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC₅₀ value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.

HY-163372

PROTAC HPK1 Degrader-1	PROTACs MAP4K	Cancer
PROTAC HPK1 Degrader-1 (Compound B1) is a potent HPK1 degrader with DC₅₀ value of 1.8 nM. PROTAC HPK1 Degrader-1 inhibits phosphorylation of the SLP76 protein with IC₅₀ value of 496.1 nM. PROTAC HPK1 Degrader-1 is a bona fide HPK1-PROTAC degrader, which provided a potential tool for further HPK1 investigation in TCR signaling .

HY-16637D

Folic acid disodium 15+ Cited Publications Vitamin B9 disodium; Vitamin M disodium	Endogenous Metabolite DNA/RNA Synthesis	Others Neurological Disease Cancer
Folic acid disodium (Vitamin B9 disodium; Vitamin M disodium) is an orally active disodium salt form of Folic acid (HY-16637) with an intrinsic dissolution rate (IDR) of 4.96·10 ⁵ g/s . Folic acid disodium serves as cofactor in single-carbon transfer reactions and exhibits protective effects against neural tube defects, ischemic events, and cancer. Folate acid disodium overload leads to impaired brain development in embryogenesis and promotes growth of precancerous altered cells. Folic acid deficiency leads to megaloblastic anemia .

HY-168081

PD-1/PD-L1-IN-52	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-52 (Compound III-5) is an orally active PD-1/PD-L1 inhibitor that blocks the interaction between PD-1 and PD-L1, with an IC₅₀ of 109.9 nM. PD-1/PD-L1-IN-52 exhibits antitumor activity in a C57BL/6 mouse xenograft model implanted with human PD-1-expressing MC38 colon cancer cells, with a TGI of 49.6% .

HY-147826

EGFR-IN-60	EGFR Apoptosis	Cancer
EGFR-IN-60 (Compound 7d) shows obvious inhibition of EGFR ^WT, EGFR ^T790M, EGFR ^L858R and JAK3 with IC₅₀s of 83, 26, 53, and 69 nM, respectively. EGFR-IN-60 potently inhibits the growth of H1975 cells harboring EGFR ^T790M mutation (IC₅₀=1.32 µM) over A431 cells overexpressing EGFR ^WT (IC₅₀=4.96 µM). EGFR-IN-60 exhibits good oral absorption, potent and safe antitumor activity. EGFR-IN-60 induces cell death through apoptosis supported by increased Bax/Bcl-2 ratio .

HY-145258

GABAA receptor agent 6	GABA Receptor	Neurological Disease
GABAA receptor agent 6 (compound 2027) is a potent γ-GABAAR antagonist with an K_i of 0.56 µM. GABAA receptor agent 6 shows γ-GABAAR antagonist activity with low cellular membrane permeability .

Cat. No.	Product Name	Type